Trial Profile

Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Oropharyngeal cancer; Squamous cell cancer
Focus Pharmacodynamics
Acronyms CIAO

Most Recent Events

16 Mar 2021 Status changed from active, no longer recruiting to completed.
08 Apr 2020 Primary endpoint (Change of CD8+ tumor infiltrating lymphocytes) has not been met, according to results published in the Clinical Cancer Research
08 Apr 2020 Results (data cutoff date: 8 Nov 2019) were published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com